Related Experiment Video

Updated: Jun 15, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:37

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

103

Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease

Jingyuan Ma1, Wai Han Yiu1, Sydney C W Tang1

  • 1Division of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

Diabetic Medicine : a Journal of the British Diabetic Association
|August 27, 2024
PubMed

Insights

Diabetic kidney disease (DKD) involves inflammation and fibrosis, with complement anaphylatoxins C3a and C5a playing key roles. Targeting these anaphylatoxins offers a promising therapeutic strategy for DKD patients.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Diabetic kidney disease (DKD) is a leading cause of kidney failure, marked by chronic inflammation and fibrosis.
  • The complement system, particularly anaphylatoxins C3a and C5a, is increasingly recognized for its role in DKD pathogenesis.
  • Anaphylatoxins mediate critical processes including inflammation, oxidative stress, and fibrosis in the kidney.

Purpose of the Study:

  • To review the involvement of complement anaphylatoxins in the pathogenesis of diabetic kidney disease.
  • To highlight the roles of C3a and C5a in DKD-related glomerulopathy, tubulointerstitial damage, and immune cell infiltration.
  • To discuss the potential of novel anti-diabetic drugs targeting the complement system.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of the role of complement anaphylatoxins in DKD.
  • Evaluation of complement blockade and targeted therapeutics.

Main Results:

  • Anaphylatoxins C3a and C5a are key mediators in DKD development and progression.
  • These molecules contribute to glomerulopathy, tubulointerstitial damage, and inflammation in DKD.
  • Complement blockade has shown promise in preclinical DKD models.

Conclusions:

  • Anaphylatoxins are significant contributors to DKD pathophysiology.
  • Targeting anaphylatoxins represents a potential therapeutic avenue for DKD.
  • Future therapies may focus on complement system modulation for DKD treatment.
Keywords:
anaphylatoxinscomplementdiabetic kidney disease

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

524
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
824
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
512